Graves disease (GD) is the most common cause of hyperthyroidism, accounting for more than 90% of cases in Korea. Patients with GD are treated with any of the following: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy. Most patients begin treatment with ATDs, and clinical guidelines suggest that the appropriate treatment period is 12 to 18 months. While RAI treatment and surgery manage thyrotoxicosis by destroying or removing thyroid tissue, ATDs control thyrotoxicosis by inhibiting thyroid hormone synthesis and preserving the thyroid gland. Although ATDs efficiently control thyrotoxicosis symptoms, they do not correct the main etiology of GD; therefore, frequent relapses can follow. Recently, a large amount of data has been collected on long-term ATDs for GD, and low-dose methimazole (MMZ) is expected to be a good option for remission. For the long-term management of recurrent GD, it is important to induce remission by evaluating the patient’s drug response, stopping ATDs at an appropriate time, and actively switching to surgery or RAI therapy, if indicated. Continuing drug treatment for an extended time is now encouraged in patients with a high possibility of remission with low-dose MMZ. It is also important to pay attention to the quality of life of the patients. This review aimed to summarize the appropriate treatment methods and timing of treatment transition in patients who relapsed several times while receiving treatment for GD.
Citations
Citations to this article as recorded by
Commentary: Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial Madhukar Mittal, Azher Rizvi Frontiers in Endocrinology.2024;[Epub] CrossRef
Total Thyroidectomy – A Cost-effective Alternative to Anti-Thyroid Drugs in the Management of Grave's Disease Erivelto Volpi, Leonardo M. Volpi Clinical Thyroidology.2023; 35(5): 183. CrossRef
Evaluation of the Abbott Alinity i Thyroid-Stimulating Hormone Receptor Antibody (TRAb) Chemiluminescent Microparticle Immunoassay (CMIA) Deborah J. W. Lee, Soon Kieng Phua, Yali Liang, Claire Chen, Tar-Choon Aw Diagnostics.2023; 13(16): 2707. CrossRef
Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review Robert M Branstetter, Rahib K Islam, Collin A Toups, Amanda N Parra, Zachary Lee, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye Cureus.2023;[Epub] CrossRef
Cerebral venous sinus thrombosis (CVT) is a rare cerebrovascular condition accounting for 0.5–1% of all types of strokes in the general population. Hyperthyroidism is associated with procoagulant and antifibrinolytic activity, thereby precipitating a hypercoagulable state that predisposes to CVT. We report the case of a 31-year-old Korean man with massive CVT and diagnosis of concomitant Graves’ disease at admission. Early diagnosis and prompt treatment of CVT are important to improve prognosis; therefore, CVT should be considered in the differential diagnosis in all patients with hyperthyroidism presenting with neurological symptoms.
Citations
Citations to this article as recorded by
Associations between deep venous thrombosis and thyroid diseases: a two-sample bidirectional Mendelian randomization study Lifeng Zhang, Kaibei Li, Qifan Yang, Yao Lin, Caijuan Geng, Wei Huang, Wei Zeng European Journal of Medical Research.2024;[Epub] CrossRef
Association Between Thyrotoxicosis and Cerebral Venous Thrombosis Margherita Paccagnella, Anna Pizzo, Veronica Calabrò, Valerio Velardi, Bruno Fabris, Stella Bernardi Journal of Clinical Medicine.2024; 13(21): 6547. CrossRef
Cerebral Sinus Vein Thrombosis and Gender: A Not Entirely Casual Relationship Tiziana Ciarambino, Pietro Crispino, Giovanni Minervini, Mauro Giordano Biomedicines.2023; 11(5): 1280. CrossRef
Insights Into a Hypercoagulable Case of Thyrocardiac Disease and Literature Overview Pin-Yi Wu, Ruchika Meel Annals of Internal Medicine: Clinical Cases.2023;[Epub] CrossRef
Cerebral Venous Thrombosis during Thyrotoxicosis: Case Report and Literature Update Emanuela Maria Raho, Annibale Antonioni, Niccolò Cotta Ramusino, Dina Jubea, Daniela Gragnaniello, Paola Franceschetti, Francesco Penitenti, Andrea Daniele, Maria Chiara Zatelli, Maurizio Naccarato, Ilaria Traluci, Maura Pugliatti, Marina Padroni Journal of Personalized Medicine.2023; 13(11): 1557. CrossRef
Unprovoked Isolated Pulmonary Embolism and Graves’ Disease in a Patient With Dyspnea: A Case Report Roshan Bisural, Deepak Acharya, Samaj Adhikari, Baikuntha Chaulagai, Arjun Mainali, Tutul Chowdhury, Nicole Gousy Cureus.2022;[Epub] CrossRef
Cerebral venous sinus thrombosis caused by traumatic brain injury complicating thyroid storm: a case report and discussion Shurong Gong, Wenyao Hong, Jiafang Wu, Jinqing Xu, Jianxiang Zhao, Xiaoguang Zhang, Yuqing Liu, Rong-Guo Yu BMC Neurology.2022;[Epub] CrossRef
Severe headache as a monosymptom of cerebral venous sinus thrombosis: a case report with effective utilization of the SNNOOP10 approach Garik Yeganyan, Hasmik Sargsyan, Mariam Manukyan, Henrik Schytz, Samson Khachatryan Armenian Journal of Health & Medical Sciences.2022; : 52. CrossRef
Hyperthyroidism as a Precipitant Factor for Cerebral Venous Thrombosis: A Case Report Ahmed Elkhalifa Elawad Elhassan, Mohammed Omer Khalil Ali, Amina Bougaila, Mohammed Abdelhady, Hassan Abuzaid Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef
Mid-ventricular obstruction (MVO) rarely occurs in patients without hypertrophic cardiomyopathy. Increased cardiac contractility may play an important role in causing MVO. We experienced a case of severe chest pain and MVO in a 50-year-old female patient. She had hypertension, diabetes, stroke and peripheral artery disease. Her blood pressure was very high (222/122 mmHg) with severe fluctuation. The transthoracic echocardiography revealed MVO accompanied by hyper-dynamic left ventricular systolic function. We regarded her chest pain and MVO as secondary findings related to other diseases. Coronary angiography and several tests for uncontrolled hypertension were performed, and those evaluations revealed that she had coronary artery disease and hyperthyroidism. We considered that the increase in the myocardial oxygen demand in response to the increase in cardiac contractility and workload associated with hyperthyroidism aggravated her symptoms and MVO. She was treated with methimazole and beta blockers and her symptoms dramatically improved.
There has been an increase in the number of reports of atypical manifestations of Graves' disease (GD), such as jaundice, anemia, thrombocytopenia and leukopenia. Pancytopenia also rarely occurs in GD. In this paper, a case of pancytopenia with GD that was successfully treated with an anti-thyroid drug is reported. In this case, a 69-year-old woman showed pancytopenia with a normal peripheral blood smear, bone marrow aspiration smear and bone marrow biopsy. Her thyroid function test and thyroid scintigraphy confirmed her hyperthyroid status. Her laboratory abnormality and clinical condition improved after she was treated with an anti-thyroid drug. This is a rare case of pancytopenia associated with GD.
Citations
Citations to this article as recorded by
Therapeutic plasma exchange for Graves’ disease in pregnancy Matthew Lumchee, Mimi Yue, Josephine Laurie, Adam Morton Obstetric Medicine.2023; 16(2): 126. CrossRef
Non-myeloproliferative Pancytopenia: A Rare Presentation of Thyrotoxicosis Izzathunnisa Rahmathullah, Maheswaran Umakanth, Suranga Singhapathirane Cureus.2023;[Epub] CrossRef
Atypical Complications of Graves’ Disease: A Case Report and Literature Review Khaled Ahmed Baagar, Mashhood Ahmed Siddique, Shaimaa Ahmed Arroub, Ahmed Hamdi Ebrahim, Amin Ahmed Jayyousi Case Reports in Endocrinology.2017; 2017: 1. CrossRef